The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| XERS | +135.41% | +35.98% | +6.33% | +204% |
| S&P | +13.19% | +87.83% | +13.42% | +54% |
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $74.38M | 37.1% |
| Gross Profit | $60.67M | 59.8% |
| Gross Margin | 81.57% | 11.6% |
| Market Cap | $1.31B | 209.5% |
| Market Cap / Employee | $3.34M | 0.0% |
| Employees | 394 | 4.5% |
| Net Income | $0.62M | 103.9% |
| EBITDA | $9.92M | 201.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $91.60M | 54.6% |
| Accounts Receivable | $53.75M | 30.7% |
| Inventory | 67.5 | 49.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $251.46M | 0.6% |
| Short Term Debt | $6.19M | -70.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -4.52% | 14.9% |
| Return On Invested Capital | -46.97% | 29.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $18.36M | 318.8% |
| Operating Free Cash Flow | $18.43M | 321.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -17.83 | -27.70 | -20.74 | -67.99 | 353.43% |
| Price to Sales | 2.49 | 3.76 | 3.03 | 5.43 | 139.70% |
| Price to Tangible Book Value | -3.31 | -5.42 | -4.72 | -9.67 | 248.11% |
| Price to Free Cash Flow TTM | 144.94 | - | |||
| Enterprise Value to EBITDA | 146.56 | 19759.23 | 123.28 | 162.49 | -353.49% |
| Free Cash Flow Yield | 0.7% | - | |||
| Return on Equity | -324.2% | -617.2% | - | ||
| Total Debt | $271.45M | $268.75M | $257.22M | $257.65M | -4.91% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
